Skip to content

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
13.4×+13.3×
Replimune Group logo
Replimune GroupREPL
0.4×+0.2×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
0.0×
Erasca, Inc. logo
Erasca, Inc.ERAS
0.1×0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.2×+0.1×

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+71.8%
Enterprise value-$7.49M-130%

Returns & leverage

See full
Return on equity-42.7%
Current ratio13.8×+2.6×

Where this comes from

Calculated from OnKure Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s debt-to-equity?
OnKure Therapeutics, Inc. (OKUR) reported debt-to-equity of 0× in Q1 2026.
How has OnKure Therapeutics, Inc.'s debt-to-equity changed year-over-year?
OnKure Therapeutics, Inc.'s debt-to-equity decreased by 79.0% year-over-year, from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.